-
1
-
-
34247568441
-
Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy
-
Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007; 5: 632–4.
-
(2007)
J Thromb Haemost
, vol.5
, pp. 632-634
-
-
Khorana, A.A.1
Francis, C.W.2
Culakova, E.3
Kuderer, N.M.4
Lyman, G.H.5
-
2
-
-
0038718518
-
Venous thromboembolism and cancer: risks and outcomes
-
Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation 2003; 107: I17–21.
-
(2003)
Circulation
, vol.107
, pp. I17-21
-
-
Lee, A.Y.1
Levine, M.N.2
-
3
-
-
13444256137
-
Malignancies, prothrombotic mutations, and the risk of venous thrombosis
-
Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293: 715–22.
-
(2005)
JAMA
, vol.293
, pp. 715-722
-
-
Blom, J.W.1
Doggen, C.J.2
Osanto, S.3
Rosendaal, F.R.4
-
4
-
-
0037775584
-
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer
-
Lee AY, Levine MN, Baker RI, Bowden C, Kakker AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146–53.
-
(2003)
N Engl J Med
, vol.349
, pp. 146-153
-
-
Lee, A.Y.1
Levine, M.N.2
Baker, R.I.3
Bowden, C.4
Kakker, A.K.5
Prins, M.6
Rickles, F.R.7
Julian, J.A.8
Haley, S.9
Kovacs, M.J.10
Gent, M.11
-
5
-
-
84940649946
-
Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial
-
Lee AY, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF, Khorana AA. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA 2015; 314: 677–86.
-
(2015)
JAMA
, vol.314
, pp. 677-686
-
-
Lee, A.Y.1
Kamphuisen, P.W.2
Meyer, G.3
Bauersachs, R.4
Janas, M.S.5
Jarner, M.F.6
Khorana, A.A.7
-
6
-
-
84916639141
-
Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
-
Akl EA, Kahale L, Barba M, Neumann I, Labedi N, Terrenato I, Sperati F, Muti P, Schunemann H. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2014; 7: Cd006650.
-
(2014)
Cochrane Database Syst Rev
, vol.7
, pp. Cd006650
-
-
Akl, E.A.1
Kahale, L.2
Barba, M.3
Neumann, I.4
Labedi, N.5
Terrenato, I.6
Sperati, F.7
Muti, P.8
Schunemann, H.9
-
7
-
-
0030184305
-
Effect of syringe size on bruising following subcutaneous heparin injection
-
Hadley SA, Chang M, Rogers K. Effect of syringe size on bruising following subcutaneous heparin injection. Am J Crit Care 1996; 5: 271–6.
-
(1996)
Am J Crit Care
, vol.5
, pp. 271-276
-
-
Hadley, S.A.1
Chang, M.2
Rogers, K.3
-
8
-
-
84930182283
-
Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study
-
Francis CW, Kessler CM, Goldhaber SZ, Kovacs Mj, Monreal M, Huisman MV, Bergqvist D, Turpie AG, Ortel TL, Spyropoulos AC, Pabinger I, Kakker AK. Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study. J Thromb Haemost 2015; 13: 1028–35.
-
(2015)
J Thromb Haemost
, vol.13
, pp. 1028-1035
-
-
Francis, C.W.1
Kessler, C.M.2
Goldhaber, S.Z.3
Kovacs, M.4
Monreal, M.5
Huisman, M.V.6
Bergqvist, D.7
Turpie, A.G.8
Ortel, T.L.9
Spyropoulos, A.C.10
Pabinger, I.11
Kakker, A.K.12
-
9
-
-
33748498896
-
Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period
-
Deitcher SR, Kessler CM, Merli G, Rigas JR, Lyons RM, Fareed J. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost 2006; 12: 389–96.
-
(2006)
Clin Appl Thromb Hemost
, vol.12
, pp. 389-396
-
-
Deitcher, S.R.1
Kessler, C.M.2
Merli, G.3
Rigas, J.R.4
Lyons, R.M.5
Fareed, J.6
-
10
-
-
84865805653
-
Management and adherence to VTE treatment guidelines in a national prospective cohort study in the Canadian outpatient setting. The Recovery Study
-
Kahn SR, Springmann V, Schulman S, Martineau J, Stewart JA, Komari N, McLeod A, Strulovitch C, Blostein M, Faucher JP, Gamble G, Gordon W, Kagoma PK, Miron MJ, Laverdiere D, Game M, Mills A. Management and adherence to VTE treatment guidelines in a national prospective cohort study in the Canadian outpatient setting. The Recovery Study. Thromb Haemost 2012; 108: 493–8.
-
(2012)
Thromb Haemost
, vol.108
, pp. 493-498
-
-
Kahn, S.R.1
Springmann, V.2
Schulman, S.3
Martineau, J.4
Stewart, J.A.5
Komari, N.6
McLeod, A.7
Strulovitch, C.8
Blostein, M.9
Faucher, J.P.10
Gamble, G.11
Gordon, W.12
Kagoma, P.K.13
Miron, M.J.14
Laverdiere, D.15
Game, M.16
Mills, A.17
-
11
-
-
84961198226
-
Adherence to treatment guidelines for cancer-associated thrombosis: a French hospital-based cohort study
-
Mahe I, Puget H, Buzzi JC, Lamuraglia M, Chidia J, Strukov A, Helfer H, Peroziello A. Adherence to treatment guidelines for cancer-associated thrombosis: a French hospital-based cohort study. Support Care Cancer 2016; 8: 3369–77.
-
(2016)
Support Care Cancer
, vol.8
, pp. 3369-3377
-
-
Mahe, I.1
Puget, H.2
Buzzi, J.C.3
Lamuraglia, M.4
Chidia, J.5
Strukov, A.6
Helfer, H.7
Peroziello, A.8
-
12
-
-
84928499067
-
Treatment of venous thromboembolism in ambulatory cancer patients in Germany: a prospective non-interventional study
-
Matzdorff A, Schilling H, Ledig B. Treatment of venous thromboembolism in ambulatory cancer patients in Germany: a prospective non-interventional study. Oncol Res Treat 2015; 38: 174–80.
-
(2015)
Oncol Res Treat
, vol.38
, pp. 174-180
-
-
Matzdorff, A.1
Schilling, H.2
Ledig, B.3
-
13
-
-
84875263410
-
Anticoagulant use in patients with cancer associated venous thromboembolism: a retrospective cohort study
-
Rahme E, Feugere G, Sirois C, Weicker S, Ramos E. Anticoagulant use in patients with cancer associated venous thromboembolism: a retrospective cohort study. Thromb Res 2013; 131: 210–17.
-
(2013)
Thromb Res
, vol.131
, pp. 210-217
-
-
Rahme, E.1
Feugere, G.2
Sirois, C.3
Weicker, S.4
Ramos, E.5
-
14
-
-
84904335836
-
Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism
-
van der Hulle T, den Exter PL, Kooiman J, van der Hoeven JJ, Huisman MV, Klok FA. Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism. J Thromb Haemost 2014; 12: 1116–20.
-
(2014)
J Thromb Haemost
, vol.12
, pp. 1116-1120
-
-
van der Hulle, T.1
den Exter, P.L.2
Kooiman, J.3
van der Hoeven, J.J.4
Huisman, M.V.5
Klok, F.A.6
-
15
-
-
84874965931
-
Diagnostic management of acute deep vein thrombosis and pulmonary embolism
-
Huisman MV, Klok FA. Diagnostic management of acute deep vein thrombosis and pulmonary embolism. J Thromb Haemost 2013; 11: 412–22.
-
(2013)
J Thromb Haemost
, vol.11
, pp. 412-422
-
-
Huisman, M.V.1
Klok, F.A.2
-
16
-
-
23044505564
-
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients
-
Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 692–4.
-
(2005)
J Thromb Haemost
, vol.3
, pp. 692-694
-
-
Schulman, S.1
Kearon, C.2
-
17
-
-
84923821726
-
Estimating risk of venous thromboembolism in patients with cancer in the presence of competing mortality
-
Ay C, Posch F, Kaider A, Zielinski C, Pabinger I. Estimating risk of venous thromboembolism in patients with cancer in the presence of competing mortality. J Thromb Haemost 2015; 13: 390–7.
-
(2015)
J Thromb Haemost
, vol.13
, pp. 390-397
-
-
Ay, C.1
Posch, F.2
Kaider, A.3
Zielinski, C.4
Pabinger, I.5
-
18
-
-
84896741977
-
Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis
-
van der Hulle T, Kooiman J, den Exter PL, Dekkers OM, Klok FA, Huisman MV. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost 2014; 12: 320–8.
-
(2014)
J Thromb Haemost
, vol.12
, pp. 320-328
-
-
van der Hulle, T.1
Kooiman, J.2
den Exter, P.L.3
Dekkers, O.M.4
Klok, F.A.5
Huisman, M.V.6
-
19
-
-
84893418928
-
Management of venous thromboembolism in cancer patients and the role of the new oral anticoagulants
-
Wharin C, Tagalakis V. Management of venous thromboembolism in cancer patients and the role of the new oral anticoagulants. Blood Rev 2014; 28: 1–8.
-
(2014)
Blood Rev
, vol.28
, pp. 1-8
-
-
Wharin, C.1
Tagalakis, V.2
-
20
-
-
84983095266
-
Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study
-
van Es N, Di Nisio M, Bleker SM, Segers A, Mercuri MF, Schwocho L, Kakkar A, Weitz Ji, Beyer-Westendorf J, Boda Z, Carrier M, Chlumsky J, Decousus H, Garcia D, Gibbs H, Kamphuisen PW, Monreal M, Ockelford P, Pabinger I, Verhamme P, et al. Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study. Thromb Haemost 2015; 114: 1268–76.
-
(2015)
Thromb Haemost
, vol.114
, pp. 1268-1276
-
-
van Es, N.1
Di Nisio, M.2
Bleker, S.M.3
Segers, A.4
Mercuri, M.F.5
Schwocho, L.6
Kakkar, A.7
Weitz, J.8
Beyer-Westendorf, J.9
Boda, Z.10
Carrier, M.11
Chlumsky, J.12
Decousus, H.13
Garcia, D.14
Gibbs, H.15
Kamphuisen, P.W.16
Monreal, M.17
Ockelford, P.18
Pabinger, I.19
Verhamme, P.20
more..
|